Esperion Therapeutics

Traded on the St. Petersburg Stock Exchange
Esperion Therapeutics, Inc. is a public American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C.
Esperion Therapeutics stock price chart
vol.
change
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential

Esperion Therapeutics balance sheet

Report period2018 2019 2020 2021 2022 Q3 23
End date of the reporting period
Capitalization, $
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

Esperion Therapeutics cash flows

Report period2018 2019 2020 2021 2022 Q3 23 TTM
End date of the reporting period
Sales
Gross profit
Operation Income
Earnings
Shareholders earnings
EBITDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS

Esperion Therapeutics multipliers

Report period2018 2019 2020 2021 2022 Q3 23 TTM
P/E
E/P
P/B
P/S
P/FCF
L/A
Debt-To-Equity
Net Debt/EBITDA
EV/EBITDA

Esperion Therapeutics profitability

Report period2018 2019 2020 2021 2022 Q3 23 TTM
ROA
ROE
ROS
Gross margin
EBITDA Margin
Operating margin
Esperion Therapeutics assets
Esperion Therapeutics cash flows

Esperion Therapeutics shares

TickerNameTypeNominal valueISINPrice
ESPR:USEsperion Therapeutics, Inc.Common share-US29664W1053$2.29
Esperion Therapeutics news
03.05.2022
Esperion Therapeutics' GAAP loss for 3 months of 2022 was $56.731 million, down 37.6% from $90.935 million in the previous year. Revenue increased 2.4 times to $18.836 million from $7.978 million a year earlier.
Source: {source} pictogram esperion.com
Pictogram next
22.02.2022
Esperion Therapeutics' GAAP loss for 2021 was $269.108 million, up 87.5% from $143.551 million in the previous year. Revenue decreased 2.9 times to $78.447 million from $227.547 million a year earlier.
Source: {source} pictogram esperion.com
Pictogram next
02.11.2021
Esperion Therapeutics' GAAP loss for 9M 2021 was $203.989 million, up 5.2 times from $39.075 million in the previous year. Revenue decreased 3.5 times to $63.046 million from $217.909 million a year earlier.
Source: {source} pictogram esperion.com
Pictogram next
03.08.2021
Esperion Therapeutics reported a GAAP loss of $134.603 million for the six months of 2021, compared to a profit of $46.362 million in the previous year. Revenue fell 4.4 times to $48.637 million from $214.076 million a year earlier.
Source: {source} pictogram esperion.com
Pictogram next
All Esperion Therapeutics news
General information
Company nameEsperion Therapeutics
SectorHealth Care / Pharmaceuticals, Biotechnology & Life Sciences / Biotechnology / Biotechnology
Business address3891 RANCHERO DRIVE, SUITE 150 ANN ARBOR MI 48108 734-887-3903
Mailing address3891 RANCHERO DRIVE, SUITE 150 ANN ARBOR MI 48108
Websitewww.esperion.com
Information disclosurewww.sec.gov